Samit Govindji Hathi
Oprichter bij Gowrie Laxmico Ltd.
Profiel
Samit Govindji Hathi is the founder of Gowrie Laxmico Ltd., where he holds the title of Chief Executive Officer & Director starting in 1999.
He is currently a Director at Laxmi BNS Holdings Ltd., Syri Ltd.
(United Kingdom), Laxmico Ltd., and Novalgen Ltd.
Actieve functies van Samit Govindji Hathi
Bedrijven | Functie | Begin |
---|---|---|
Gowrie Laxmico Ltd.
Gowrie Laxmico Ltd. Medical DistributorsDistribution Services Gowrie Laxmico Ltd. distributes pharmaceutical products. The company was founded on October 8, 1997 and is headquartered in Middlesex, the United Kingdom. | Oprichter | 01-01-1999 |
Laxmi BNS Holdings Ltd.
Laxmi BNS Holdings Ltd. Drugstore ChainsRetail Trade Founded in 2010, Laxmi BNS Holdings Ltd. is a pharmaceutical distribution and British sales company. The company is based in Ruislip, UK. | Directeur/Bestuurslid | 10-02-2010 |
Laxmico Ltd.
Laxmico Ltd. Medical DistributorsDistribution Services Part of Gowrie Laxmico Ltd., Laxmico is a wholesaler of pharmaceutical products. The company is based in Ruislip, UK. Laxmico was founded in 2009. | Directeur/Bestuurslid | - |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Directeur/Bestuurslid | - |
Syri Ltd. (United Kingdom)
Syri Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Gowrie Holdings Ltd., Syri Ltd. is a British UK-based company founded in 2010. The company specializes in the development, licensing, manufacture, and marketing of liquid medicines. | Directeur/Bestuurslid | 02-12-2010 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
Gowrie Laxmico Ltd.
Gowrie Laxmico Ltd. Medical DistributorsDistribution Services Gowrie Laxmico Ltd. distributes pharmaceutical products. The company was founded on October 8, 1997 and is headquartered in Middlesex, the United Kingdom. | Distribution Services |
Laxmi BNS Holdings Ltd.
Laxmi BNS Holdings Ltd. Drugstore ChainsRetail Trade Founded in 2010, Laxmi BNS Holdings Ltd. is a pharmaceutical distribution and British sales company. The company is based in Ruislip, UK. | Retail Trade |
Syri Ltd. (United Kingdom)
Syri Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Gowrie Holdings Ltd., Syri Ltd. is a British UK-based company founded in 2010. The company specializes in the development, licensing, manufacture, and marketing of liquid medicines. | Health Technology |
Laxmico Ltd.
Laxmico Ltd. Medical DistributorsDistribution Services Part of Gowrie Laxmico Ltd., Laxmico is a wholesaler of pharmaceutical products. The company is based in Ruislip, UK. Laxmico was founded in 2009. | Distribution Services |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |